Earnings Feed
Start Free
Cadrenal Therapeutics, Inc.·4

Jun 10, 8:26 PM ET

Pham Quang X 4

Research Summary

AI-generated summary

Updated

Cadrenal Therapeutics (CVKD) 10% Owner Pham Quang Sells 22,385 Shares

What Happened
Pham Quang, a reported 10% owner of Cadrenal Therapeutics (CVKD), sold a total of 22,385 common shares in three open-market transactions between June 8–10, 2026, for aggregate proceeds of about $93,294. Individual transactions reported: 5,893 shares on 2026-06-08 at a weighted avg $4.38 ($25,811), 12,992 shares on 2026-06-09 at a weighted avg $4.06 ($52,748), and 3,500 shares on 2026-06-10 at a weighted avg $4.21 ($14,735). These sales were reported under the sale code (S).

Key Details

  • Transaction dates and reported weighted-average prices:
    • 2026-06-08: 5,893 sh @ $4.38; weighted price range for these trades reported as $4.20–$4.51 (footnote F2).
    • 2026-06-09: 12,992 sh @ $4.06; weighted price range reported as $4.03–$4.34 (footnote F3).
    • 2026-06-10: 3,500 sh @ $4.21; weighted price range reported as $4.20–$4.23 (footnote F4).
  • Total sold: 22,385 shares for approx. $93,294.
  • These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 25, 2025 (footnote F1).
  • Ownership/beneficial interest note: The filer is Trustee of The PVBQ Living Trust and has sole voting and dispositive power over shares held by that trust (footnote F5).
  • Shares owned after the transactions: Not disclosed in the provided filing details.
  • Filing date: Form 4 filed 2026-06-10 covering transactions from 2026-06-08 through 06-10; filing appears timely (no late-filing flag reported).

Context

  • These were sales (S) by a 10% owner under a pre-established 10b5-1 plan — a common mechanism that allows scheduled sales and reduces the implication of opportunistic trading. For retail investors, purchases generally signal stronger insider conviction than routine sales; these transactions should be viewed as disposition activity by a large shareholder rather than an explicit endorsement or rejection of company prospects.
  • The filing notes weighted-average prices and ranges because each line represents multiple executions; the reporting person has offered to provide transaction-level price details on request.